share_log

Oppenheimer Reiterates Outperform on Dyne Therapeutics, Maintains $47 Price Target

Benzinga ·  May 6 07:55

Oppenheimer analyst Francois Brisebois reiterates Dyne Therapeutics (NASDAQ:DYN) with a Outperform and maintains $47 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment